Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein Cy, R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2. R3, R4, R5, R6, R7, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: Representative implementations of devices and techniques provide an adjustable drum pedal assembly. One or more levers may be slideably adjustable with respect to a drive shaft of the pedal. The one or more levers may include a mount for a drum beater, a drive cam mechanism, or the like. Further, a footboard of the pedal may be slideably adjustable with respect to a position relative to the drive shaft.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: Representative implementations of devices and techniques provide an adjustable drum pedal assembly. One or more levers may be slideably adjustable with respect to a drive shaft of the pedal. The one or more levers may include a mount for a drum beater, a drive cam mechanism, or the like. Further, a footboard of the pedal may be slideably adjustable with respect to a position relative to the drive shaft.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: A method for reducing NOx in a selective catalytic reduction (SCR) fossil-fuel fired boiler includes the steps of providing a first set of optical measurement devices adapted to measure NOx and NH3 concentrations contained in an exhaust stream from a fossil-fuel fired boiler, performing measurements of NOx and NH3 at an SCR inlet using the first set of optical measurement devices, and determining an NH3/NOx molar ratio using the measurements taken by the first set of optical measurement devices. The method further includes the steps of using the determined NH3/NOx molar ratio in comparison against a user specified NH3/NOx molar ratio set-point, and controlling an NH3 control valve to match ammonia flow to changes in boiler NOx emissions such that the molar ratio set-point is maintained.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: Memory systems and devices are provided. One memory system includes a controller configured to be coupled to a plurality of computing devices, a plurality of Multi-Level Cell (MLC) devices coupled to the controller, and a Single-Level Cell (SLC) device coupled to the controller and the plurality of MLC devices. The MLC devices are configured to split the storage of data across the plurality of MLC devices and the SLC device is configured to function as a parity device for the data. A memory device includes a controller, a plurality of MLC FLASH devices, and a SLC FLASH device. The MLC FLASH devices are configured to split the storage of data across the plurality of MLC FLASH devices and the SLC FLASH device is configured to function as a parity device for the data. Also provided are computing devices including the above memory device.

Abstract: A system and method for determining user response to wireless messages, comprising means for generating a wireless message including first content to be transmitted, means for adding second content to the message, the second content including a link to third content and means for transmitting the message to the user, wherein, in response to activation of the link, information regarding link activation is arranged to be recorded in a storage means. The link may be a URL or a telephone number of a redirection server that deals with redirection to the third content as well as logging of user responses.

Abstract: The invention relates to displaying content at a mobile device. In some embodiments, a method and apparatus are arranged to display content at a mobile device in association with a graphical device indicating a method of user interaction associated with the content. The mobile device is arranged to detect, at a detector such as a motion detector or on a touch screen of the mobile device, a user interaction and to determine whether the user interaction corresponds to the indicated method of interaction. The method and apparatus are arranged to perform an action relating to the content in response to the detection of the indicated method of interaction.